In breast cancer patients receiving aromatase inhibitor treatment, short-term (≤18 months) celecoxib or low-dose aspirin use did not improve event-free survival or distant disease-free survival, and low-dose aspirin use even increased all-cause mortality (Strasser-Weippl et al., 2018). This evidence concerns the gene CYP19A1 and breast cancer.